Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies - Quiz - MDSpire

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies

  • By

  • Abhijnan Chattopadhyay

  • Aminat O. Dosunmu

  • Darshan Reddy

  • Sree Dharma

  • Krishna Panchal

  • Callie S. Kwartler

  • Dianna M. Milewicz

  • July 13, 2026

Share

Original Source(s)

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies

  • by Abhijnan Chattopadhyay, Aminat O. Dosunmu, Darshan Reddy, Sree Dharma, Krishna Panchal, Callie S. Kwartler, Dianna M. Milewicz

  • July 13, 2026

Related Content

Sentara opens 1st stand-alone vascular care center in Hampton Roads

New outpatient center in Norfolk brings faster, more convenient vascular care to dialysis and chemotherapy patients across the region.

  • by

  • July 13, 2026

  • 3 min
Adjunctive role of p16/Ki-67 dual-stain cytology in colposcopy referral pathways for cervical precancer and persistent high-risk HPV infection

A versatile distance-based approach for gene expression selection across diverse biological systems